Purple Biotech Ltd.提交了价值 600 万美元的公开发行招股说明书，并可能通过认股权证额外筹集 1200 万美元

Purple Biotech Ltd., a clinical-stage company focused on developing therapies to combat tumor immune evasion and drug resistance, has announced the pricing of a public offering involving 5,999,999 American Depositary Shares (ADSs) and short-term warrants to purchase up to 11,999,998 ADSs. Each ADS represents 200 ordinary shares, with a combined public offering price set at $1.00 per share. These short-term warrants are exercisable immediately and will expire 24 months from issuance. The offering, facilitated by H.C. Wainwright & Co. as the exclusive placement agent, is pursuant to a registration statement on Form F-1 filed with the SEC. The gross proceeds are estimated to be approximately $6 million, with potential additional proceeds of $12 million if the short-term warrants are fully exercised. The funds are intended for the development of oncology therapeutic candidates and general corporate purposes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Purple Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-084858), on September 05, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here